2/10
The NEO-RT trial can be opened through SWOG Cancer Research Network NRG Oncology Alliance for Clinical Trials in Oncology ECOG-ACRIN Cancer Research Group and is supported by our study champions. Chris Cann, MD Noam VanderWalde

New article (Vol 193)

Short course RT versus RCT for locally advanced rectal cancers in the elderly (UNICANCER PRODIGE 42/GERICO 12 study): Quality of life and comprehensive geriatric assessment
Eric François et al.

doi.org/10.1016/j.rado…

thegreenjournal.com/article/S0167-…

🚨🚨🚨
EXTEND Trial

Oligometastatic PDAC

Randomized SOC vs +/- oligometastasis directed radiotherapy (MDT)

🔥 Addition of MDT improves PFS: 10.3 vs. 2.5 months, HR 0.43, p=0.03

👏🏽👏🏽 Ethan Ludmir MD and team!!!
#GI24

Older adults with cancer are an increasing proportion of the cancer population and will become nearly 70% of all diagnoses in coming years #SIOG23 Noam VanderWalde SIOG

Thank you ⁦Kristin Higgins⁩ for an excellent discussion and pointing out age restrictions. #ASTRO23 #gerionc

Meta-analysis Tumor Treating Fields (TTF) 9 studies, 1430 pts GBM
· Median OS 23mos w/TTF vs 17 mos w/o
· Usage rate ≥75% associated ↑OS
rdcu.be/dihp3

The new MUST READ paper for geriatric oncologist is here! Many thanks and congrats to all the Authors! SIOG Young SIOG

Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update ascopubs.org/doi/10.1200/JC…

.Reshma Jagsi and colleagues from @swog find low rates of locoregional recurrence and questionable role of regional nodal irradiation for #breastcancer on landmark trial S1007. Omission of chemotherapy not independent indication regional nodal irradiation. ja.ma/44A051V

Be at the Heart of the #SIOG2023 Action!
Book your Meliá Valencia hotel stay NOW to save money, stay in the venue hosting the SIOG Annual Conference, and receive more chances to network. #GeriOnc loom.ly/Y_PiiGU

I am technically OOO until August, but I couldn’t miss being there for Hyman Muss MD last day of clinic. Hy, you’ve taught me so much during my last year of fellowship, and I know your patients will miss you. Thanks for everything!

Johns Hopkins Kimmel Cancer Center Podcasts: On Target with Dr Akila Viswanathan - Personalization of Cancer Care for Older Adults for Seminars in Radiation Oncology #gerionc #radonc hopkinskimmel.libsyn.com/on-target-with…

#GeriatricOncology is a strong field of interest for our Radiation Oncologist & Co-Director of Clinical Research, Dr. Noam VanderWalde.

In this  #podcast , he discusses the importance of personalization for older cancer patients alongside Dr Akila Viswanathan & Dr Ben Movsas!

The European Society for Radiotherapy and Oncology (ESTRO) issued the following statement regarding the PROSPECT clinical trial for patients with resectable rectal cancer: lnkd.in/eAKgFCru

#radiotherapy #radiationoncology #radonc

40 years ago this was predicted. The field of GO was marginalized as a niche field. All oncologists are geriatric oncologists. We are mainstream oncology. #gerionc #asco #carg dailymail.co.uk/health/article…

Congrats to all of the OPRA investigators and Julio Garcia Aguilar - 5-year data presented today by Floris Verheij Memorial Sloan Kettering Cancer Center ; LCRT --> FOLFOX: higher rates of organ preservation, lower rates of local regrowth AND no decrement in oncologic outcomes ASCO; #ASCO23 ASCRS_1

Excellent discussion of the #rectalcancer PROSPECT trial by Dr. Corrie Marijnen, MD, PhD #ASCO23

From a pt POV, we want our care team of #medonc , #radonc & surgeons to work with us to find a treatment strategy for maximal benefit with minimum side effects

#CRCSM OncoAlert

Congrats to the authors of the PROSPECT trial! A tremendous accomplishment. #ASCO23 Some thoughts:

M. Bolton Alliance for Clinical Trials in Oncology This is a great point. I don’t think it’s a “pure” take at de-intensification. Also, some may be suitable to surgery alone, eg. Upper T3N0 with no risk factors. Real key in my opinion is appropriate generalization of the data to the correct patients

PROSPECT: many patients would have qualified for upfront surgery w/o RT per ASTRO & ESMO guidelines. Then, potential de-escalation of adj chemo pending pathologic findings.

6 months of FOLFOX in experimental arm of PROSPECT likely overtreatment for a proportion.

#ASCO23

Great work Matthew B West Cancer Center & Research Institute West Cancer Center: Research Department on presenting Real-world experience with Tumor Treating Fields for #GBM #Glioblastoma at the #ASCO23 poster session! ASCO Novocure Novocure